Jefferies International Has Just Reaffirmed GBX 280.00 Target Price Per Share on Indivior Plc (LON:INDV) stock, While They’ve Also Reiterated Their Buy Rating

Share

Indivior Plc (LON:INDV) Rating Reaffirmed

Recently, In an analyst research report finalized on Tuesday, 15 December, Indivior Plc (LON:INDV) shares have had their Buy Rating has decided to reaffirm by equity research analysts at Jefferies International, who currently has a GBX 280.00 TP on firm. This target by Jefferies International may imply the possibile upside of 44.33% from the close price.

From a total of 6 analysts covering Indivior Plc (LON:INDV) stock, 5 rate it a ”Buy”, 0 a “Sell”, and 1 a ”Hold”. This means that 83% of the ratings are positive. The highest target price is GBX 4.71 while the lowest target price is GBX 3.42. The mean of all analyst targets is GBX 3.93 with a 38.66% above today’s (GBX 194) stock price. Indivior Plc was the topic of 20 analyst reports since July 29, 2015 according to the firm StockzIntelligence Inc. Stifel Nicolaus maintained shares on December 10 with “Buy” rating. Citigroup upgraded shares to “Buy” rating and GBX 270 target share price in a report from a September 22. Jefferies maintained INDV stock in a recent report from November 25 with “Buy” rating. Finally, Morgan Stanley maintained the stock with “Equal-Weight” rating in a report issued on a July 24.

The stock decreased 0.77% or GBX 1.5 on December 14, striking GBX 194. Approximately 1.09M shares of stock traded hands. Indivior PLC (LON:INDV) has declined 15.65% since May 18, 2015 and is downtrending. It has underperformed by 11.24% the S&P500.

Jefferies International Has Just Reaffirmed GBX 280.00 Target Price Per Share on Indivior Plc (LON:INDV) stock, While They’ve Also Reiterated Their Buy Rating

Indivior PLC is a specialty pharmaceutical company. The company has a market cap of 1.39 billion GBP. The Firm and its subsidiaries are engaged in the development, manufacture, and sale of buprenorphine prescription drugs for the treatment of opioid dependence. It has 7.86 P/E ratio. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine overdose and the co-morbidity of schizophrenia.

COMMENTS: